X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
prexasertib (10) 10
cancer (6) 6
index medicus (6) 6
article (4) 4
chk1 (4) 4
deoxyribonucleic acid--dna (4) 4
oncology (4) 4
tumors (4) 4
checkpoint kinase 1 - antagonists & inhibitors (3) 3
checkpoint kinase 1 inhibitor (3) 3
dna damage (3) 3
dna-replication (3) 3
humans (3) 3
pharmacology & pharmacy (3) 3
activation (2) 2
ataxia (2) 2
bioindicators (2) 2
biomarkers (2) 2
biotechnology (2) 2
cancer therapies (2) 2
cell biology (2) 2
cell cycle (2) 2
cell lines (2) 2
cells (2) 2
combination (2) 2
dna repair (2) 2
dna replication (2) 2
dna-damage response (2) 2
female (2) 2
gemcitabine (2) 2
head (2) 2
homologous recombination (2) 2
inhibitors (2) 2
initiation (2) 2
kinases (2) 2
ly-2606368 (2) 2
neutropenia (2) 2
olaparib (2) 2
patients (2) 2
pembrolizumab (2) 2
phosphorylation (2) 2
pyrazines - therapeutic use (2) 2
pyrazoles - therapeutic use (2) 2
replication (2) 2
replication stress (2) 2
squamous cell carcinoma (2) 2
adenosine triphosphatase (1) 1
adult (1) 1
aged (1) 1
albumin (1) 1
anal carcinoma (1) 1
anemia (1) 1
anemia - chemically induced (1) 1
anemia - epidemiology (1) 1
animals (1) 1
antineoplastic agents - pharmacokinetics (1) 1
antineoplastic agents - pharmacology (1) 1
antineoplastic agents - therapeutic use (1) 1
antitumor activity (1) 1
anus (1) 1
apoptosis (1) 1
atac-seq (1) 1
atr (1) 1
azd7762 (1) 1
biochemistry (1) 1
biochemistry & molecular biology (1) 1
biology (1) 1
biomarkers, tumor - genetics (1) 1
biomarkers, tumor - metabolism (1) 1
blood-brain barrier (1) 1
brain - blood supply (1) 1
brain - metabolism (1) 1
brca1 protein (1) 1
breast cancer (1) 1
calibration (1) 1
camptothecin (1) 1
cancer cells (1) 1
carcinoma (1) 1
carcinoma, squamous cell - drug therapy (1) 1
carcinoma, squamous cell - genetics (1) 1
carcinoma, squamous cell - metabolism (1) 1
carcinoma, squamous cell - pathology (1) 1
care and treatment (1) 1
catastrophe (1) 1
cdkn2a (1) 1
cell activation (1) 1
cell cycle checkpoint kinase inhibitor (1) 1
cell cycle checkpoints (1) 1
cell death (1) 1
cell lung-cancer (1) 1
cell proliferation (1) 1
cerebellar neoplasms - blood (1) 1
cerebellar neoplasms - drug therapy (1) 1
checkpoint kinase 1 (1) 1
checkpoint kinase inhibitor (1) 1
chemistry, analytical (1) 1
chemoresistance (1) 1
chemotherapy (1) 1
child (1) 1
chk1 and homologous recombination (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 67, pp. 111026 - 111040
PARP inhibitors (PARPi) have been effective in high-grade serous ovarian cancer (HGSOC), although clinical activity is limited against BRCA wild type HGSOC.... 
Cell cycle checkpoint kinase inhibitor | LY2606368 | Olaparib | Prexasertib | PARP inhibitor | REPLICATION CATASTROPHE | DNA-DAMAGE RESPONSE | OPEN-LABEL | DEATH | cell cycle checkpoint kinase inhibitor | CELL BIOLOGY | RADIOSENSITIZATION | CHK1 | prexasertib | olaparib | HOMOLOGOUS RECOMBINATION | MUTATIONS | CARCINOMA
Journal Article
BREAST CANCER RESEARCH, ISSN 1465-5411, 09/2019, Volume 21, Issue 1, pp. 104 - 14
Background Breast cancer remains as one of the most lethal types of cancer in women. Among various subtypes, triple-negative breast cancer (TNBC) is the most... 
DNA-DAMAGE RESPONSE | Olaparib | DRUG-RESISTANCE | OVARIAN-CANCER | Prexasertib | S-PHASE CHECKPOINT | CHK1 INHIBITION | LUNG-CANCER | REPAIR | RAD51 | CISPLATIN | ONCOLOGY | CHK1 and homologous recombination | CHEMORESISTANCE | TNBC | Care and treatment | Chemotherapy | Usage | Cancer cells | Breast cancer | Research | Cancer
Journal Article
Cancer Research, ISSN 0008-5472, 02/2018, Volume 78, Issue 3, pp. 781 - 797
Checkpoint kinase inhibitors (CHKi) exhibit striking single-agent activity in certain tumors, but the mechanisms accounting for hypersensitivity are poorly... 
CATASTROPHE | ONCOLOGY | PHOSPHORYLATION | INITIATION | GAMMA-H2AX | S-PHASE | NEUROBLASTOMA | GENOMIC CHARACTERIZATION | LINES | CHECKPOINT KINASE INHIBITOR | DNA-REPLICATION | Cyclin-Dependent Kinase 2 - metabolism | Sequence Deletion | Cell Proliferation | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Carcinoma, Squamous Cell - pathology | Humans | Checkpoint Kinase 1 - antagonists & inhibitors | Enzyme Inhibitors - pharmacology | Head and Neck Neoplasms - drug therapy | Cyclin-Dependent Kinase 2 - genetics | DNA Replication | Head and Neck Neoplasms - metabolism | Head and Neck Neoplasms - pathology | Carcinoma, Squamous Cell - drug therapy | Cyclin-Dependent Kinase Inhibitor p18 - genetics | S Phase | Biomarkers, Tumor - metabolism | Head and Neck Neoplasms - genetics | Antineoplastic Agents - pharmacology | Biomarkers, Tumor - genetics | Enzyme Activation | Tumor Cells, Cultured | Apoptosis | Therapy | Biotechnology | Copy number | Activation | Clonal deletion | Deletion | Bioindicators | Deoxyribonucleic acid--DNA | Stresses | Squamous cell carcinoma | Head | Genomic analysis | Hypersensitivity | CHK1 protein | Tumor cell lines | Patients | Stress | DNA biosynthesis | Cyclin-dependent kinase 2 | Inhibitors | Cell lines | Biomarkers | Replication | Strategy | Head and neck cancer | Tumors | Cancer | replication stress | CDKN2A | p16 deletions | HNSCC | prexasertib
Journal Article
Journal Article
Cancer Science, ISSN 1347-9032, 10/2018, Volume 109, Issue 10, pp. 3216 - 3223
Journal Article
Drugs of the Future, ISSN 0377-8282, 2017, Volume 42, Issue 9, pp. 555 - 563
Journal Article
DRUGS OF THE FUTURE, ISSN 0377-8282, 09/2017, Volume 42, Issue 9, pp. 555 - 563
Prexasertib (LY-2606368) is a second-generation checkpoint kinase (Chk) 1 and Chk2 inhibitor being developed as a novel cancer therapy. The drug candidate was... 
Checkpoint kinase 1 inhibitor | PHARMACOLOGY & PHARMACY | LY-2606368 | Prexasertib | Cancer
Journal Article
by Watt, J
Drugs of the Future, ISSN 0377-8282, 2016, Volume 41, Issue 11, pp. 699 - 701
The 2016 edition of the Annual ESMO Congress brought stakeholders in the medical oncology area to Copenhagen and gave them a platform on which to present... 
Pembrolizumab | Nivolumab | MEDI-0680 | Prexasertib | WK-0202 | PHARMACOLOGY & PHARMACY
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.